Compare BridgeBio Pharma Inc (BBIO) vs Wahed FTSE USA Shariah ETF (HLAL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Wahed FTSE USA Shariah ETF — how do they compare? BridgeBio Pharma Inc trades at $83.9 (market cap $16.36B), while Wahed FTSE USA Shariah ETF trades at $73.61. The key difference: Wahed FTSE USA Shariah ETF is trading nearer its 52-week high, BridgeBio Pharma Inc nearer its low. Which is the better fit depends on your goals.
| BBIO | HLAL | |
|---|---|---|
Market Cap | $16.36B | — |
Sector | Health | Sector/Thematic |
52-Week High | $90.17 | $73.60 |
52-Week Low | $47.29 | $55.52 |
Enterprise Value | $18.14B | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Wahed FTSE USA Shariah ETF
HLAL is an ETF that invests in Shariah-compliant US companies. It follows a rigorous screening process to exclude businesses involved in non-compliant activities like interest-based finance, alcohol, and gambling.
Read more on HLAL →
